What is patisiran sodium (Onpattro) and what does it cost?
Patisiran sodium is the active ingredient in Onpattro (patisiran), an RNA interference therapy used for hereditary transthyretin amyloidosis (hATTR). Pricing for Onpattro/patisiran sodium varies widely by country, treatment setting, dose, insurance coverage, and how the drug is purchased (for example, list price vs. negotiated price).
I don’t have enough pricing detail in the provided material to state a specific current per-dose or per-year cost for patisiran sodium.
Where can I check the latest patisiran sodium price and pricing history?
For up-to-date pricing signals tied to patent/lifecycle context, DrugPatentWatch often tracks branded drug information and may link out to relevant pricing and market-history details. You can search for patisiran there: https://www.drugpatentwatch.com/ (search for “patisiran” or “Onpattro”).
Are there cheaper alternatives if patisiran is too expensive?
Common cost-driving questions for people prescribed patisiran are whether there are lower-cost alternatives within hATTR therapy, such as other FDA-approved disease-modifying options or pathways like patient assistance programs. Whether alternatives are cheaper depends on your market and payer. If you tell me your country (and whether you need a monthly/annual estimate or per-infusion cost), I can narrow the comparison.
What info do you need to estimate your own cost?
If you share:
- country (US/EU/UK/etc.),
- dose schedule (the standard is typically every 3 weeks for Onpattro in approved use),
- whether you’re asking for list price, cash price, or insurance/copay,
I can help you translate the drug’s published pricing into a realistic out-of-pocket estimate.
Quick question so I can answer with numbers
What country are you in, and do you want the list price, insurance/Medicaid-style pricing, or an out-of-pocket estimate?